Selway Asset Management’s Biogen BIIB Stock Holding History

Selway Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	-$80K	–	84
2022 Q3	$80K	Buy	+300	New	+$63.7K	0.05%	84

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Selway Asset Management's BIIB Position: Q4 2022 in Review

Selway Asset Management sold out of Biogen (BIIB) in Q4 2022, closing a stake of 300 shares — an estimated $80K sold.

Selway Asset Management first reported a position in BIIB in Q3 2022 and held it in 1 quarter. The position peaked at $80K in Q3 2022. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Selway Asset Management reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Selway Asset Management sold 300 Biogen shares in Q4 2022, an estimated $80K.
Selway Asset Management first reported a position in Biogen in Q3 2022 and held it in 1 quarter.
Selway Asset Management's Biogen position peaked at $80K in Q3 2022.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Selway Asset Management's 13F filing for Q4 2022, filed 17 Feb 2023.